AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 22731873
Drug: Aerosolized albuterol
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized albuterol (5 mg) every 4 hours for up to 10 days
Trial: 22731873
Drug: Aerosolized albuterol
RxNorm normalized name: Albuterol Inhalation Aerosol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aerosolized albuterol (5 mg)
Trial: 16500364
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of clomiphene citrate alone (group A, n = 65)
Trial: 16500364
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg of clomiphene citrate plus hCG (group B, n = 60)
Trial: 28850471
Drug: IM morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IM morphine
Trial: 6537870
Drug: Isolated soy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated soy protein with 1.6% L‐methionine supplementation
Trial: 6537870
Drug: Isolated soy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isolated soy protein with 1.1% L‐methionine supplementation
Trial: 26937646
Drug: CartiJoint Forte
RxNorm normalized name: Erythroped Forte
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CartiJoint Forte (two tablets daily for 8 weeks)
Trial: 24065463
Drug: AAV1/SERCA2a high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV1/SERCA2a high-dose (1×10(13) DNase-resistant particles)
Trial: 24065463
Drug: AAV1/SERCA2a low-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV1/SERCA2a low-dose (6×10(11) DNase-resistant particles)
Trial: 24065463
Drug: AAV1/SERCA2a mid-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AAV1/SERCA2a mid-dose (3×10(12) DNase-resistant particles)
Trial: 18480923
Drug: NB‐UVB plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NB‐UVB plus antihistamine
Trial: 18480923
Drug: Antihistamine (control)
RxNorm normalized name: Ahist Antihistamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antihistamine (control)
Trial: 15737948
Drug: Hydrocortisone (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrocortisone (loading dose of 100 mg followed by continuous infusion of 0.18 mg/kg/h for 6 days)
Trial: 2142271
Drug: Intracutaneous injections
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracutaneous injections of sterile water
Trial: 2142271
Drug: Subcutaneous injections
RxNorm normalized name: immune globulin subcutaneous (human) - klhw Injection [Xembify]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous injections of isotonic saline (placebo)
Trial: 699486
Drug: Ibuprofen (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (600 mg orally)
Trial: 11418517
Drug: Itraconazole oral
RxNorm normalized name: itraconazole Oral Tablet
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Itraconazole oral solution 100 mg bd
Trial: 11418517
Drug: Amphotericin B
RxNorm normalized name: Amphotericin B
DrugBank: Amphotericin B (DB00681)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amphotericin B 500 mg tds plus nystatin 2 MU qds
Trial: 9596317
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical therapy plus NPPV
Trial: 20675729
Drug: Conventional medical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional medical therapy alone
Trial: 8042719
Drug: propofol/fentanyl (4-8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: propofol/fentanyl (4-8 mg.kg‐1.h‐1, 1.2 mg.h‐1)
Trial: 8042719
Drug: isoflurane/fentanyl (0.6-1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: isoflurane/fentanyl (0.6-1.2 vol%, 1.2 mg.h‐1)
Trial: 8042719
Drug: flunitrazepam/fentanyl (1.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: flunitrazepam/fentanyl (1.2 mg.h‐1)
Trial: 2847928
Drug: Clonidine 0.45
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 0.45 mg daily for three days
Trial: 84148
Drug: Disodium cromoglycate
RxNorm normalized name: Disodium cromoglycate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disodium cromoglycate (800 mg daily)
Trial: 7872274
Drug: Sulphasalazine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulphasalazine (2 g daily)
Trial: 84148
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of disodium cromoglycate and sulphasalazine
Trial: 30671722
Drug: Experimental treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Experimental treatments (stove exchanges and free stoves)
Trial: 29735484
Drug: Inclisiran 200
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran 200 mg single-dose
Trial: 29735484
Drug: Inclisiran 300
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran 300 mg 2-dose
Trial: 29735484
Drug: Inclisiran 500
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Inclisiran 500 mg single-dose
Trial: 26822398
Drug: Afatinib plus
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib plus vinorelbine (40 mg/day afatinib + 25 mg/m² vinorelbine per week)
Trial: 26822398
Drug: Trastuzumab plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trastuzumab plus vinorelbine (2 mg/kg trastuzumab per week after 4 mg/kg loading dose + 25 mg/m² vinorelbine per week)
Trial: 25707822
Drug: Chemical method
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemical method (2% R. communis solution)
Trial: 22594388
Drug: Back School
RxNorm normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Back School (active therapy, ergonomics, and education)
Trial: 11965272
Drug: Control (alternative
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (alternative analgesic regimens with general anaesthesia)
Trial: 2698241
Drug: Optrex Eye
RxNorm normalized name: docosahexaenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optrex Eye Lotion (self-administered by irrigation into the left eye three times daily for seven days)
Trial: 2698241
Drug: Optrex Eye
RxNorm normalized name: docosahexaenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optrex Eye Lotion (self-administered in the right eye by 15 patients)
Trial: 2698241
Drug: Optrex Eye
RxNorm normalized name: docosahexaenoate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Optrex Eye Lotion
Trial: 183554
Drug: Metronidazole (750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronidazole (750 mg three times daily for 5 days)
Trial: 183554
Drug: Tinidazole (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tinidazole (1 g twice daily on 2 consecutive days)
Trial: 24725803
Drug: Human insulin
RxNorm normalized name: Human insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Human insulin (HI)
Trial: 23857221
Drug: Metformin (1.5-2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1.5-2.5 g per day)
Trial: 20528207
Drug: Metformin plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin plus low-dose oral contraceptive (ethinyl oestradiol-cyproterone acetate, EE/CA) 850 mg metformin twice a day for three cycles
Trial: 19423131
Drug: Alprazolam and
RxNorm normalized name: Alprazolam and propranolol only product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alprazolam and investigational compound
Trial: 15255788
Drug: Low-dose dopamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dopamine (5 micro g kg(‐1) min(‐1))
Trial: 29273827
Drug: Eldecalcitol (ELD;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eldecalcitol (ELD; 0.75 μg/day)
Trial: 29273827
Drug: 1α hydroxyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1α hydroxyl calcidiol (ALF; 1 μg/day)
Trial: 28167659
Drug: Ibrutinib 560
RxNorm normalized name: ibrutinib 560 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibrutinib 560 mg orally once daily until progression or unacceptable toxicity
Trial: 10806607
Drug: Verapamil (80
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verapamil (80 mg) and Metoprolol (50 mg) together
Trial: 10180860
Drug: Vitamin D
RxNorm normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin D injection
Trial: 1710921
Drug: MOPP-ABVD alternating
RxNorm normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MOPP-ABVD alternating regimen (monthly alternating one cycle of MOPP and one cycle of ABVD)
Trial: 19685114
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg bupivacaine (group B)
Trial: 19638454
Drug: MTX and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MTX and SSZ combination therapy
Trial: 16990992
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human MBL (rhMBL) 0.01, 0.05, 0.1, and 0.5 mg/kg single intravenous infusions
Trial: 16990992
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human MBL (rhMBL) 0.1 or 0.3 mg/kg repeated intravenous infusions at 3-day intervals
Trial: 16990992
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human MBL (rhMBL) 0.5 mg/kg single intravenous infusion
Trial: 11046206
Drug: Inhaled albuterol
RxNorm normalized name: albuterol Inhalation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled albuterol (4 puffs, 15-20 min before intubation)
Trial: 11046206
Drug: Intravenous lidocaine
RxNorm normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravenous lidocaine (1.5 mg/kg, 3 min before intubation)
Trial: 8375519
Drug: Intramuscular hCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intramuscular hCG (10,000 IU)
Trial: 8375519
Drug: Intravenous hCG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hCG (500 IU)
Trial: 21901320
Drug: Scopolamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scopolamine (0.5 mg)
Trial: 3018822
Drug: Methscopolamine (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methscopolamine (0.75 mg)
Trial: 22999808
Drug: Ipratropium bromide/salbutamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ipratropium bromide/salbutamol sulfate (500 μg/2.5 mg) combination
Trial: 18294310
Drug: Oral alitretinoin
RxNorm normalized name: Alitretinoin
DrugBank: Alitretinoin (DB00523)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral alitretinoin 10 mg once daily for up to 24 weeks
Trial: 12637478
Drug: 4 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 cycles of BEP chemotherapy (bleomycin, etoposide, cisplatin) over 5 days
Trial: 12637478
Drug: 3 cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 cycles of BEP chemotherapy (bleomycin, etoposide, cisplatin) over 3 days
Trial: 8611382
Drug: Cyclophosphamide (600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclophosphamide (600 mg m‐2) administered every 3 weeks for three courses with prednisone and interferon‐alpha2b
Trial: 8611382
Drug: Epirubicin (70
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epirubicin (70 mg m‐2) administered every 3 weeks for three courses with prednisone and interferon‐alpha2b
Trial: 1416333
Drug: Pressurized saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pressurized saline canister (220 mL saline at 8 psi)
Trial: 1416333
Drug: Syringe irrigation
RxNorm normalized name: Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Syringe irrigation (250 mL saline)
Trial: 4074604
Drug: Reproterol 1
RxNorm normalized name: reproterol
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reproterol 1 mg
Trial: 4074604
Drug: Reproterol 8
RxNorm normalized name: reproterol
DrugBank: Reproterol (DB12846)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reproterol 8 mg
Trial: 4074604
Drug: Reproterol (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reproterol (various doses)
Trial: 12492903
Drug: 0.0625% P‐113
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.0625% P‐113 gel
Trial: 12492903
Drug: 0.125% P‐113
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.125% P‐113 gel
Trial: 12492903
Drug: 0.375% P‐113
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375% P‐113 gel
Trial: 12492903
Drug: P‐113 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: P‐113 treatment groups
Trial: 1632542
Drug: 0.25% bupivacaine
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.25% bupivacaine with epinephrine (5 micrograms/mL)
Trial: 1632542
Drug: 0.5% bupivacaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% bupivacaine with epinephrine (5 micrograms/mL)
Trial: 6092287
Drug: Activated charcoal,
RxNorm normalized name: activated charcoal, sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal, 50 g given within 5 min of sotalol hydrochloride (160 mg)
Trial: 6092287
Drug: Activated charcoal,
RxNorm normalized name: activated charcoal, sterile
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Activated charcoal, repeated doses of 50 g followed by 12.5 g at 6 h intervals
Trial: 30882914
Drug: 400 or
RxNorm normalized name: Nico-400 Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 400 or 800 mg UDCA on day 1, followed by 200 mg UDCA twice daily for 2 weeks
Trial: 26875065
Drug: Intra-articular injection
RxNorm normalized name: PHOSPHORUS P-32 5 mCi in 1 mL INTRA-ARTICULAR INJECTION, SUSPENSION
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular injection (IA group)
Trial: 26875065
Drug: Subacromial injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subacromial injection (SA group)
Trial: 26875065
Drug: Combined IA
RxNorm normalized name: magnesium aluminum silicate type Ia
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined IA and subacromial injections (IA+SA group)
Trial: 24390400
Drug: Intracameral injection
RxNorm normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Intracameral injection of balanced salt solution (sham injection)
Trial: 22112807
Drug: Once-daily (OD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily (OD) hydrocortisone dual-release tablet
Trial: 20715787
Drug: Three novel
RxNorm normalized name: three-lobe sage extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three novel nonsteroidal glucocorticoid receptor agonists applied at low dose in ethanol solution.
Trial: 17697555
Drug: GEMOX regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GEMOX regimen (gemcitabine of fixed-dose rate infusion plus oxaliplatin)
Trial: 16913264
Drug: Fexofenadine, 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fexofenadine, 180 mg
Trial: 2270767
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg fluconazole (oral)
Trial: 2270767
Drug: 1200 mg
RxNorm normalized name: aspirin 1200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1200 mg miconazole (intravaginal)
Trial: 17458505
Drug: AZD2171 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2171 at 2.5 mg
Trial: 17458505
Drug: AZD2171 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2171 at 20 mg
Trial: 17458505
Drug: AZD2171 at
RxNorm normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2171 at 30 mg
Trial: 17458505
Drug: AZD2171 (various
FDA approved: no
EMA approved: no
PMDA approved: no
Description: AZD2171 (various doses)
Trial: 15138906
Drug: 20 mg
RxNorm normalized name: urea 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 mg ropivacaine plus 0.1 mg morphine
Trial: 15138906
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg bupivacaine plus 0.1 mg morphine
Trial: 12011536
Drug: Piperacillin/tazobactam 4.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam 4.5 g q6h
Trial: 12011536
Drug: Piperacillin/tazobactam 3.375
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Piperacillin/tazobactam 3.375 g q4h
Trial: 26545513
Drug: Traditional Treatment
RxNorm normalized name: Midol Traditional
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Treatment
Trial: 23870217
Drug: Surgicel (oxidized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgicel (oxidized cellulose patch)
Trial: 15192621
Drug: High-dose levothyroxine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose levothyroxine (12.0 microg/kg per day)
Trial: 9333592
Drug: Magnesium sulfate
RxNorm normalized name: Magnesium Sulfate
DrugBank: Magnesium (DB14513)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Magnesium sulfate 4,000 mg
Trial: 9333592
Drug: Magnesium glutamate
RxNorm normalized name: magnesium glutamate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium glutamate 2 x 1,000 mg intravenously
Trial: 9333592
Drug: Magnesium injection
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium injection
Trial: 24722235
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy with prednisone and metronidazole (D‐CT, n=10)
Trial: 3538446
Drug: Oral trimeprazine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral trimeprazine, droperidol and methadone (TDM)
Trial: 3538446
Drug: No sedative
RxNorm normalized name: MedActive Rinse
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No sedative medication (unsedated group)
Trial: 26852375
Drug: Psychoeducational intervention
RxNorm normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Psychoeducational intervention program (PIP) with 12 weekly group sessions
Trial: 31170361
Drug: Intermittent Intensive
RxNorm normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intermittent Intensive Insulin Therapy (IIT)
Trial: 19960983
Drug: Metformin (Control)
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Metformin (Control)
Trial: 21596190
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine S(+) 0.050 mg/kg
Trial: 21596190
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine S(+) 0.125 mg/kg
Trial: 21596190
Drug: Intravenous ketamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ketamine S(+) 0.250 mg/kg
Trial: 19389820
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injections (MDI) with insulin glargine and lispro
Trial: 11255387
Drug: Ibutilide (0.003
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibutilide (0.003 mg/kg), infused intravenously for 10 minutes.
Trial: 9572724
Drug: traditional self‐administered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: traditional self‐administered questionnaire
Trial: 8186337
Drug: Lansoprazole (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lansoprazole (30 mg each morning, placebo at bedtime)
Trial: 8186337
Drug: Ranitidine (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine (150 mg each morning and at bedtime)
Trial: 2896139
Drug: Delayed-release mesalazine
RxNorm normalized name: mesalamine Delayed Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Delayed-release mesalazine
Trial: 28985228
Drug: Treatment as
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment as usual (N = 148)
Trial: 23427212
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (manual administration)
Trial: 22352122
Drug: Early titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Early titration (E) with irbesartan/hydrochlorothiazide 150/12.5 mg for 2 weeks, then up-titrated to 300/25 mg at weeks 2 and 6
Trial: 22352122
Drug: Late titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late titration (L) with irbesartan/hydrochlorothiazide 150/12.5 mg for 6 weeks, then up-titrated to 300/25 mg at week 6
Trial: 14765987
Drug: l-thyroxine treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: l-thyroxine treatment regimen
Trial: 11083889
Drug: Ciprofloxacin (800‐1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin (800‐1200 mg/day)
Trial: 11083889
Drug: Imipenem (2‐4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imipenem (2‐4 g/day)
Trial: 9068468
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin (250 mg b.i.d.)
Trial: 9068468
Drug: Oral ciprofloxacin
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ciprofloxacin and Placebo
Trial: 2658581
Drug: Ciprofloxacin treatment
RxNorm normalized name: Ciprofloxacin
DrugBank: Ciprofloxacin (DB00537)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ciprofloxacin treatment